MLA
KPTI icon

MB, Levis & Associates’s Karyopharm Therapeutics KPTI Stock Holding History

MB, Levis & Associates’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$977 Hold
100
– – ﹤0.01% 242
2026
Q1 		$557 Hold
100
– – ﹤0.01% 225
2025
Q4 		$736 Hold
100
– – ﹤0.01% 234
2025
Q3 		$654 Hold
100
– – ﹤0.01% 235
2025
Q2 		$431 Hold
100
– – ﹤0.01% 257
2025
Q1 		$374 Hold
100
– – ﹤0.01% 270
2024
Q4 		$1.01K Hold
100
– – ﹤0.01% 266
2024
Q3 		$1.25K Hold
100
– – ﹤0.01% 263
2024
Q2 		$1.3K Hold
100
– – ﹤0.01% 260
2024
Q1 		$2.27K Hold
100
– – ﹤0.01% 251
2023
Q4 		$1.3K Hold
100
– – ﹤0.01% 248
2023
Q3 		$2.01K Hold
100
– – ﹤0.01% 247
2023
Q2 		$2.69K Hold
100
– – ﹤0.01% 238
2023
Q1 		$5.83K Hold
100
– – ﹤0.01% 216
2022
Q4 		$5.1K Buy
+100
New +$6.93K ﹤0.01% 207

Other funds holding KPTI

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
WBC
West Branch Capital Amherst, Massachusetts $430M AUM 41.9% 1-Year Est. Return

MB, Levis & Associates's KPTI Position: Q2 2026 in Review

MB, Levis & Associates held its Karyopharm Therapeutics (KPTI) position steady in Q2 2026 at 100 shares worth $977. The position accounts for ﹤0.01% of the portfolio, ranked #242.

MB, Levis & Associates first reported a position in KPTI in Q4 2022 and has held it in 15 quarters since. The position peaked at $5.83K in Q1 2023. 6 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • MB, Levis & Associates held 100 shares of Karyopharm Therapeutics worth $977 as of Q2 2026.
  • MB, Levis & Associates left its Karyopharm Therapeutics share count unchanged in Q2 2026.
  • Karyopharm Therapeutics made up ﹤0.01% of MB, Levis & Associates's portfolio in Q2 2026, its #242 holding.
  • MB, Levis & Associates first reported a position in Karyopharm Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • MB, Levis & Associates's Karyopharm Therapeutics position peaked at $5.83K in Q1 2023.
  • 6 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on MB, Levis & Associates's 13F filing for Q2 2026, filed 22 Jul 2026.